gsgs
Registered User
---------------------------
Nitazoxanide
favipiravir
fludase
JNJ63623872 (formerly known as VX-787)
S-033188
Results from a phase IIb/III human clinical trial demonstrated that 600 mg
NTZ twice daily (started within 48 hours of symptom onset) reduced symptom
duration by 36 hours.
In mice receiving the multiple dose regimen, there was a significant decrease
in viral shedding and viral load up to 5 days from the commencement of treatment.[39]
300 mg/kg dose of favipiravir=T705 resulted in nearly 100% survival rate in mice infected
with H5N1, even when treatment was started 72 hours post-infection, compared
to mice given a 50 mg/kg dosage of oseltamivir which had a 50% survival rate.[51]
results from human trials are not publicly available concerning the safety or efficacy of the drug
Administration of JNJ63623872 in mice up to 96 hours post-infection resulted in 100% survival and
was superior to oseltamivir treatment in which 100% survival was only observed when
mice were dosed up to 24 hours post-infection.[46]
The JNJ63623872 treatment group had a quicker resolution of influenza-like symptoms
(1.9 days) compared to the placebo group (3.7 days).[61]
S-033188 had significant reductions in time to alleviation of symptoms and reduced
virus titres at 24 and 48 hours post-treatment compared to placebo.[62]
phase III clinical trial (NCT02949011) since Dec.2016
http://onlinelibrary.wiley.com/doi/1...irv.12446/full
------------------------------
10/10/2017 | 10:23am CEST
[TD="colspan: 2"] [h=2] Send by mail : [/h] [/TD]
[TD="class: std_txtS, colspan: 2, align: right"] (You can enter multiple email addresses separated by commas) [/TD]
[TD="class: std_txtS, colspan: 2, align: right"] * Required fields [/TD]
[TD="colspan: 2"][/TD]
Release date- 09102017 - OSAKA, Japan and FLORHAM PARK - Shionogi & Co., Ltd. (hereafter 'Shionogi') today announced it will report results of a S-033188 Phase 3 study in otherwise healthy influenza patients (CAPSTONE-1) at IDWeek 2017, held in San Diego, October 4-8. S-033188 is a novel cap-dependent endonuclease inhibitor with potent anti-viral efficacy for the treatment of influenza.
Nitazoxanide
favipiravir
fludase
JNJ63623872 (formerly known as VX-787)
S-033188
Results from a phase IIb/III human clinical trial demonstrated that 600 mg
NTZ twice daily (started within 48 hours of symptom onset) reduced symptom
duration by 36 hours.
In mice receiving the multiple dose regimen, there was a significant decrease
in viral shedding and viral load up to 5 days from the commencement of treatment.[39]
300 mg/kg dose of favipiravir=T705 resulted in nearly 100% survival rate in mice infected
with H5N1, even when treatment was started 72 hours post-infection, compared
to mice given a 50 mg/kg dosage of oseltamivir which had a 50% survival rate.[51]
results from human trials are not publicly available concerning the safety or efficacy of the drug
Administration of JNJ63623872 in mice up to 96 hours post-infection resulted in 100% survival and
was superior to oseltamivir treatment in which 100% survival was only observed when
mice were dosed up to 24 hours post-infection.[46]
The JNJ63623872 treatment group had a quicker resolution of influenza-like symptoms
(1.9 days) compared to the placebo group (3.7 days).[61]
S-033188 had significant reductions in time to alleviation of symptoms and reduced
virus titres at 24 and 48 hours post-treatment compared to placebo.[62]
phase III clinical trial (NCT02949011) since Dec.2016
http://onlinelibrary.wiley.com/doi/1...irv.12446/full
------------------------------
10/10/2017 | 10:23am CEST
| Last Name : | |
| Name : | |
| From* : | |
| To* : | |
| Message : | |
[TD="colspan: 2"] [h=2] Send by mail : [/h] [/TD]
[TD="class: std_txtS, colspan: 2, align: right"] (You can enter multiple email addresses separated by commas) [/TD]
[TD="class: std_txtS, colspan: 2, align: right"] * Required fields [/TD]
[TD="colspan: 2"][/TD]
Release date- 09102017 - OSAKA, Japan and FLORHAM PARK - Shionogi & Co., Ltd. (hereafter 'Shionogi') today announced it will report results of a S-033188 Phase 3 study in otherwise healthy influenza patients (CAPSTONE-1) at IDWeek 2017, held in San Diego, October 4-8. S-033188 is a novel cap-dependent endonuclease inhibitor with potent anti-viral efficacy for the treatment of influenza.
Last edited: